Synapse - Brigitte Senechal

Results (34)

A Phase I trial of 19-28z CAR-T cells post-high dose therapy and autologous transplantation (HDT-ASCT) for relapsed and refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL)

Meeting Abstract

Sauter, C.; Riviere, I.; Senechal, B.; Ni, A.; Bernal, Y.; Wang, X.; Purdon, T.; Hall, M.; Moskowitz, C.; Giralt, S.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Disease burden and transplant on long-term survival after CD19 CAR T cells in adults with relapsed acute lymphoblastic leukemia

Meeting Abstract

Park, J.; Rivere, I.; Wang, X. Y.; Senechal, B.; Curran, K.; Sauter, C.; Wang, Y. Z.; Li, D.; Brentjens, R.; Sadelain, M.
Molecular Therapy (2017)

Fulltext@MSK | Save

Implications of concurrent ibrutinib therapy on CAR T-cell manufacturing and phenotype and on clinical outcomes following CD19-targeted CAR T-cell administration in adults with relapsed/refractory CLL

Meeting Abstract

Geyer, M. B.; Park, J. H.; Riviere, I.; Senechal, B.; Wang, X.; Purdon, T. J.; Sadelain, M. W.; Brentjens, R. J.
Blood (2016)

Fulltext@MSK | Save

Phase I trial: CD19-targeted CAR T-cells in patients with residual CLL following initial purine analog-based therapy

Meeting Abstract

Geyer, M.; Park, J.; Rivière, I.; Senechal, B.; Hsu, M.; Wang, X.; Purdon, T.; Sadelain, M.; Brentjens, R.
Clinical Lymphoma, Myeloma and Leukemia (2016)

Fulltext@MSK | Save